The Abdominal Aortic Aneurysm Repair Devices Market size is projected to experience a CAGR of 5.6% during the forecast period from 2026 to 2033, reaching from USD 3.12 Bn to approximately USD 4.58 Bn. Some of the factors responsible for driving the market growth are the high prevalence of abdominal aortic aneurysms in the aging population, increasing use of minimally invasive aneurysm repair procedures, advances in aortic stent-graft technology, better screening and diagnosis of aneurysms, and availability of stent-graft systems designed for patients with complex vascular anatomy. As per Cleveland Clinic, endovascular aneurysm repair is a minimally invasive technique involving the use of puncture and special tools to insert a stent graft into the aorta where the aneurysm is situated.
The Abdominal Aortic Aneurysm Repair Devices Market is gaining from the increased implementation of screening and surveillance programs. Early detection enables patients with smaller aneurysms to enter structured surveillance pathways and supports timely referral for repair when aneurysm size, growth, symptoms, or other clinical factors meet intervention criteria.
According to the UK Health Security Agency’s AAA Screening Standards Report released in February 2026, there were about 337,752 men screened for their first-time AAA examination in England from 2024 to 2025, among which 82.3% were tested conclusively. There were also 12,190 annual follow-ups, which accounted for 92.3% of those in the designated testing period.
Innovations in endovascular aneurysm repair devices are making AAA surgery more appealing to clinicians. Modern devices utilize smaller delivery systems, better graft conformability, advanced sealing systems, better fixation, and wider size options, allowing doctors to treat a greater number of patients and different vascular morphologies.
A study conducted on 150 patients from 29 centers in the United States in 2026, and published in the Journal of Vascular Surgery, has assessed the efficacy of the TREO abdominal stent-graft system. In the five-year follow-up period, 90.2 percent of the eligible patients had data available, and none of those deaths that occurred could be attributed to aneurysms.
|
Current Event |
Description and its Impact |
|
NHS England Maintains Large-Scale AAA Screening and Surgical-Referral Programme (2025–2026) |
|
|
FDA Continues Post-Approval Surveillance and Design-Control Oversight of AAA Stent Grafts (2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of product type, the stents segment, primarily comprising abdominal aortic stent-graft systems, is projected to account for the largest Abdominal Aortic Aneurysm Repair Devices Market share of 59.0% in 2026. The segment’s growth is attributed to the increasing preference for endovascular aneurysm repair, broader treatment of complex aortic anatomies, lower-profile delivery systems, improved graft conformability, and the continued development of fenestrated and branched stent-graft technologies.
The 2025 UK National Vascular Registry report recorded 2,511 elective repairs of unruptured infrarenal AAA during 2024, of which 62.7% were performed using EVAR, compared with 38.0% through open repair.
In October 2025, Medtronic received U.S. FDA labeling approval for the Endurant Stent Graft System, removing the previous warning associated with the treatment of ruptured abdominal aortic aneurysms.

To learn more about this report, Request Free Sample
On the basis of end user, the hospitals segment is projected to lead the Abdominal Aortic Aneurysm Repair Devices Market with an estimated 74.0% share in 2026. The segment’s dominance is driven by the requirement for vascular surgeons, advanced fluoroscopic imaging, hybrid operating rooms, anaesthesia support, intensive postoperative monitoring, blood-bank access, and immediate conversion to open surgery when endovascular repair complications occur.
According to the NHS England AAA Screening Standards Report updated in February 2026, 932 men were identified with a large or rapidly expanding aneurysm during 2024–2025, and 92.7% were assessed by a vascular surgeon within two weeks.
In March 2026, Baylor College of Medicine received a USD 14.4 million research award from the Marcus Foundation to establish the Marcus VITAL Laboratory within its Center for Aortic Surgery.

To learn more about this report, Request Free Sample
North America is expected to dominate the Abdominal Aortic Aneurysm Repair Devices Market with an estimated 39.8% share in 2026. The region’s leadership is supported by the high availability of vascular surgeons, hybrid operating rooms, established EVAR programs, advanced imaging infrastructure, favourable reimbursement coverage and early adoption of next-generation abdominal stent-graft systems.
Canada also has a growing addressable elderly population. Statistics Canada reported that the country had approximately 8.11 million people aged 65 years and above as of July 2025, representing 19.5% of the total population. The expanding elderly population across both the U.S. and Canada is expected to sustain demand for abdominal stent grafts, delivery sheaths, guidewires, balloons and catheters used in AAA repair.
In June 2025, MicroPort Endovastec completed the first post-market implantation of its Minos Abdominal Aortic Stent Graft and Delivery System in Malaysia.
Asia Pacific is projected to record the fastest growth in the Abdominal Aortic Aneurysm Repair Devices Market. Regional growth is being supported by rapid population aging, expansion of tertiary and specialty hospitals, improving access to vascular imaging, growing physician training in endovascular techniques and increasing availability of domestically manufactured stent-graft systems.
China’s National Bureau of Statistics reported that the country had approximately 323.38 million people aged 60 years and above in 2025, accounting for 23.0% of its population. The population aged 65 years and above reached 223.65 million, or 15.9% of the total population. China also had approximately 38,000 hospitals in 2025, providing an expanding institutional base for vascular diagnosis, surgical treatment and endovascular intervention.
In March 2026, MicroPort Scientific reported further expansion of its abdominal aortic intervention business in China.
The U.S. Abdominal Aortic Aneurysm Repair Devices Market is supported by an established endovascular-treatment infrastructure, strong physician familiarity with EVAR, comprehensive post-market surveillance and continued FDA review of stent-graft design, materials and clinical indications. These factors encourage hospitals to adopt newer abdominal stent-graft systems while supporting demand for associated sheaths, catheters, guidewires and balloons.
Medtronic’s current U.S. product information reports 99.3% delivery and deployment success for the Endurant system in its investigational device exemption study. Continued FDA-approved indication expansion and long-term evidence generation are expected to strengthen physician confidence and sustain the replacement and upgrade cycle for AAA stent-graft technologies in the U.S.
In October 2025, Medtronic received U.S. FDA labeling approval for the Endurant Stent Graft System, adding clinical evidence for ruptured abdominal aortic aneurysm treatment and removing the previous rAAA warning. Medtronic reported that ruptured AAA has a mortality rate exceeding 80%, highlighting the need for rapidly deployable endovascular systems in U.S. emergency vascular centres.
China is expected to witness strong growth in the Abdominal Aortic Aneurysm Repair Devices Market, supported by domestic stent-graft development, expanding tertiary-hospital access, NMPA regulatory pathways and increasing use of minimally invasive aortic interventions. Local manufacturers are developing lower-profile, modular and anatomically adaptable systems, which are improving device availability and reducing dependence on imported technologies.
The National Health Commission’s statistical bulletin, published in December 2025, reported that China had 38,710 hospitals in 2024, including 4,111 tertiary hospitals and 1,876 Grade III Class A hospitals. These higher-level institutions provide the imaging, vascular-surgery, anaesthesia and intensive-care capabilities required for abdominal aortic aneurysm repair.
Some of the major key players in Abdominal Aortic Aneurysm Repair Devices Market are Medtronic Plc., Cardinal Health Inc., Lombard Medical Inc., Endologix, Inc., Cook Group Incorporated, Boston Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates, Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.6% | 2033 Value Projection: | USD 4.58 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic Plc., Cardinal Health Inc., Lombard Medical Inc., Endologix, Inc., Cook Group Incorporated, Boston Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients